vs
Side-by-side financial comparison of Ovid Therapeutics Inc. (OVID) and SenesTech, Inc. (SNES). Click either name above to swap in a different company.
Ovid Therapeutics Inc. is the larger business by last-quarter revenue ($718.0K vs $421.0K, roughly 1.7× SenesTech, Inc.). On growth, Ovid Therapeutics Inc. posted the faster year-over-year revenue change (844.7% vs -16.0%). Over the past eight quarters, Ovid Therapeutics Inc.'s revenue compounded faster (120.3% CAGR vs 0.7%).
SenesTech, Inc. is an agricultural biotechnology life-sciences company, specializing in fertility management as a form of pest control. The company's primary product, ContraPest is designed to make brown and black rats infertile. SenesTech is headquartered in Phoenix, Arizona.
OVID vs SNES — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $718.0K | $421.0K |
| Net Profit | — | $-1.8M |
| Gross Margin | — | 55.3% |
| Operating Margin | — | -446.8% |
| Net Margin | — | -428.5% |
| Revenue YoY | 844.7% | -16.0% |
| Net Profit YoY | 204.4% | -43.7% |
| EPS (diluted) | — | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $718.0K | $421.0K | ||
| Q3 25 | $132.0K | $690.0K | ||
| Q2 25 | $6.3M | $625.0K | ||
| Q1 25 | $130.0K | $485.0K | ||
| Q4 24 | $76.0K | $501.0K | ||
| Q3 24 | $173.0K | $482.0K | ||
| Q2 24 | $169.0K | $459.0K | ||
| Q1 24 | $148.0K | $415.0K |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | $-12.2M | $-1.3M | ||
| Q2 25 | $-4.7M | $-1.6M | ||
| Q1 25 | $-10.2M | $-1.7M | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | $-14.0M | $-1.5M | ||
| Q2 24 | $8.5M | $-1.6M | ||
| Q1 24 | $-11.7M | $-1.8M |
| Q4 25 | — | 55.3% | ||
| Q3 25 | — | 62.8% | ||
| Q2 25 | — | 65.4% | ||
| Q1 25 | — | 64.5% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | 65.4% | ||
| Q2 24 | — | 54.2% | ||
| Q1 24 | — | 32.5% |
| Q4 25 | — | -446.8% | ||
| Q3 25 | -9487.1% | -195.2% | ||
| Q2 25 | -80.9% | -258.2% | ||
| Q1 25 | -9653.8% | -342.9% | ||
| Q4 24 | — | -250.9% | ||
| Q3 24 | -7645.1% | -321.0% | ||
| Q2 24 | -12140.2% | -349.0% | ||
| Q1 24 | -11768.2% | -444.1% |
| Q4 25 | — | -428.5% | ||
| Q3 25 | -9210.6% | -188.1% | ||
| Q2 25 | -74.7% | -258.6% | ||
| Q1 25 | -7873.1% | -343.3% | ||
| Q4 24 | — | -250.5% | ||
| Q3 24 | -8096.0% | -313.9% | ||
| Q2 24 | 5042.0% | -345.1% | ||
| Q1 24 | -7901.4% | -441.4% |
| Q4 25 | — | $0.48 | ||
| Q3 25 | — | $-0.28 | ||
| Q2 25 | — | $-0.87 | ||
| Q1 25 | — | $-1.28 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | $-0.20 | $-2.07 | ||
| Q2 24 | $0.12 | $-3.08 | ||
| Q1 24 | $-0.17 | $-3.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.2M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $130.7M | $9.6M |
| Total Assets | $150.9M | $12.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.2M | $8.6M | ||
| Q3 25 | $20.6M | $10.2M | ||
| Q2 25 | $28.4M | $6.1M | ||
| Q1 25 | $21.1M | $1.7M | ||
| Q4 24 | $26.3M | $1.3M | ||
| Q3 24 | $15.0M | $2.5M | ||
| Q2 24 | $29.7M | $2.0M | ||
| Q1 24 | $30.8M | $3.6M |
| Q4 25 | $130.7M | $9.6M | ||
| Q3 25 | $44.7M | $11.3M | ||
| Q2 25 | $55.8M | $7.0M | ||
| Q1 25 | $59.3M | $2.9M | ||
| Q4 24 | $68.2M | $2.5M | ||
| Q3 24 | $76.3M | $3.7M | ||
| Q2 24 | $88.9M | $3.1M | ||
| Q1 24 | $78.3M | $4.6M |
| Q4 25 | $150.9M | $12.8M | ||
| Q3 25 | $63.8M | $14.6M | ||
| Q2 25 | $77.4M | $10.4M | ||
| Q1 25 | $81.7M | $3.6M | ||
| Q4 24 | $92.2M | $3.3M | ||
| Q3 24 | $102.7M | $4.4M | ||
| Q2 24 | $118.1M | $4.0M | ||
| Q1 24 | $131.6M | $5.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.3M | $-1.7M |
| Free Cash FlowOCF − Capex | — | $-1.7M |
| FCF MarginFCF / Revenue | — | -398.3% |
| Capex IntensityCapex / Revenue | 0.0% | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-38.3M | $-1.7M | ||
| Q3 25 | $-12.9M | $-1.4M | ||
| Q2 25 | $-4.8M | $-1.1M | ||
| Q1 25 | $-10.3M | $-1.6M | ||
| Q4 24 | $-56.0M | $-1.2M | ||
| Q3 24 | $-15.0M | $-1.4M | ||
| Q2 24 | $-14.3M | $-1.6M | ||
| Q1 24 | $-16.7M | $-1.8M |
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | $-56.0M | $-1.2M | ||
| Q3 24 | $-15.0M | $-1.4M | ||
| Q2 24 | $-14.3M | $-1.6M | ||
| Q1 24 | $-16.7M | $-1.8M |
| Q4 25 | — | -398.3% | ||
| Q3 25 | — | -205.9% | ||
| Q2 25 | — | -191.5% | ||
| Q1 25 | — | -328.5% | ||
| Q4 24 | -73719.7% | -246.1% | ||
| Q3 24 | -8676.9% | -296.1% | ||
| Q2 24 | -8455.0% | -354.2% | ||
| Q1 24 | -11287.2% | -441.2% |
| Q4 25 | 0.0% | 3.1% | ||
| Q3 25 | 0.0% | 6.1% | ||
| Q2 25 | 0.0% | 7.5% | ||
| Q1 25 | 0.0% | 7.4% | ||
| Q4 24 | 93.4% | 3.0% | ||
| Q3 24 | 2.3% | 5.8% | ||
| Q2 24 | 20.1% | 8.5% | ||
| Q1 24 | 12.8% | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.67× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
